Terms: = Skin cancer AND RHOA, ENSG00000067560, 387, ARHA, RhoA, RHOH12, RHO12, ARH12, Rho12
198 results:
1. The Effect of Stoma Site Marking on Stomal Complications: A Long-term Retrospective Study.
Guler S; Eyuboglu G; Baykara ZG; Hin AO; Akdemir H; Akar E; Leventoglu S; Yuksel O
Adv Skin Wound Care; 2024 May; 37(5):254-259. PubMed ID: 38648238
[TBL] [Abstract] [Full Text] [Related]
2. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.
Stassen RC; Maas CCHM; van der Veldt AAM; Lo SN; Saw RPM; Varey AHR; Scolyer RA; Long GV; Thompson JF; Rutkowski P; Keilholz U; van Akkooi ACJ; Verhoef C; van Klaveren D; Grünhagen DJ
Lancet Oncol; 2024 Apr; 25(4):509-517. PubMed ID: 38547894
[TBL] [Abstract] [Full Text] [Related]
3. A combined opposite targeting of p110δ PI3K and rhoa abrogates skin cancer.
Tzenaki N; Xenou L; Goulielmaki E; Tsapara A; Voudouri I; Antoniou A; Valianatos G; Tzardi M; De Bree E; Berdiaki A; Makrigiannakis A; Papakonstanti EA
Commun Biol; 2024 Jan; 7(1):26. PubMed ID: 38182748
[TBL] [Abstract] [Full Text] [Related]
4. Identification of hub gene and lncRNA signature related to entotic cell death in cutaneous melanoma for prognostic and immune prediction.
Zhang C; Shen C
Medicine (Baltimore); 2023 Nov; 102(45):e35881. PubMed ID: 37960805
[TBL] [Abstract] [Full Text] [Related]
5. Oncogenic Gαq activates RhoJ through PDZ-RhoGEF.
Cervantes-Villagrana RD; Color-Aparicio VM; Castillo-Kauil A; García-Jiménez I; Beltrán-Navarro YM; Reyes-Cruz G; Vázquez-Prado J
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958718
[TBL] [Abstract] [Full Text] [Related]
6. Integrative multiomics analysis identifies a metastasis-related gene signature and the potential oncogenic role of EZR in breast cancer.
Xiao G; Cheng F; Yuan J; Lu W; Wang P; Fan H
Oncol Res; 2022; 30(1):35-51. PubMed ID: 37304008
[TBL] [Abstract] [Full Text] [Related]
7. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of rhoa/ROCK and CDC42/MRCK.
Wu Q; Ma X; Jin Z; Ni R; Pan Y; Yang G
J Ethnopharmacol; 2023 Oct; 315():116644. PubMed ID: 37196814
[TBL] [Abstract] [Full Text] [Related]
8. Deciphering the spectrum of cutaneous lymphomas expressing TFH markers.
Donzel M; Trecourt A; Balme B; Harou O; Mauduit C; Bachy E; Guesquières H; Fontaine J; Ortonne N; Perier-Muzet M; Dalle S; Traverse-Glehen A
Sci Rep; 2023 Apr; 13(1):6500. PubMed ID: 37081015
[TBL] [Abstract] [Full Text] [Related]
9. Innovative integration of augmented reality and optical surface imaging: A coarse-to-precise system for radiotherapy positioning.
Zhang G; Jiang Z; Zhu J; Dai T; He X; Liu X; Chang Y; Wang L
Med Phys; 2023 Jul; 50(7):4505-4520. PubMed ID: 37060328
[TBL] [Abstract] [Full Text] [Related]
10. [Subcutaneous and intramuscular heterotopic calcification of the neck 42 years after radiotherapy].
Pfiszterer P; Vass G; Rovó L; Perényi Á; Kelemen G; Bach Á
Orv Hetil; 2023 Mar; 164(10):383-387. PubMed ID: 36906861
[TBL] [Abstract] [Full Text] [Related]
11. Factors affecting eye conservation and metastasis in posterior uveal melanomas.
Nalcı Baytaroğlu H; Gündüz AK; Mirzayev I; Özalp Ateş FS
Eur J Ophthalmol; 2023 Sep; 33(5):2024-2033. PubMed ID: 36762394
[TBL] [Abstract] [Full Text] [Related]
12. YAP Activation in Promoting Negative Durotaxis and Acral Melanoma Progression.
Huang Y; Su J; Liu J; Yi X; Zhou F; Zhang J; Wang J; Meng X; Si L; Wu C
Cells; 2022 Nov; 11(22):. PubMed ID: 36428972
[TBL] [Abstract] [Full Text] [Related]
13. Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade.
Johannet P; Liu W; Fenyo D; Wind-Rotolo M; Krogsgaard M; Mehnert JM; Weber JS; Zhong J; Osman I
Clin Cancer Res; 2022 Sep; 28(18):4121-4130. PubMed ID: 36106402
[TBL] [Abstract] [Full Text] [Related]
14. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast cancer.
Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
[TBL] [Abstract] [Full Text] [Related]
15. Monensin synergizes with chemotherapy in uveal melanoma through suppressing rhoa.
Zeng C; Long M; Lu Y
Immunopharmacol Immunotoxicol; 2023 Feb; 45(1):35-42. PubMed ID: 36043455
[TBL] [Abstract] [Full Text] [Related]
16. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
Wang L; Rocas D; Dalle S; Sako N; Pelletier L; Martin N; Dupuy A; Tazi N; Balme B; Vergier B; Beylot-Barry M; Carlotti A; Bagot M; Battistella M; Chaby G; Ingen-Housz-Oro S; Gaulard P; Ortonne N
Br J Dermatol; 2022 Dec; 187(6):970-980. PubMed ID: 35895386
[TBL] [Abstract] [Full Text] [Related]
17. Secretion of IL1 by Dedifferentiated Melanoma Cells Inhibits JAK1-STAT3-Driven Actomyosin Contractility of Lymph Node Fibroblastic Reticular Cells.
Rovera C; Berestjuk I; Lecacheur M; Tavernier C; Diazzi S; Pisano S; Irondelle M; Mallavialle A; Albrengues J; Gaggioli C; Girard CA; Passeron T; Deckert M; Tartare-Deckert S; Prod'homme V
Cancer Res; 2022 May; 82(9):1774-1788. PubMed ID: 35502542
[TBL] [Abstract] [Full Text] [Related]
18. SEMA6A/rhoa/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.
Loria R; Laquintana V; Scalera S; Fraioli R; Caprara V; Falcone I; Bazzichetto C; Di Martile M; Rosanò L; Del Bufalo D; Bossi G; Sperduti I; Terrenato I; Visca P; Soddu S; Milella M; Ciliberto G; Falcioni R; Ferraresi V; Bon G
J Exp Clin Cancer Res; 2022 Apr; 41(1):148. PubMed ID: 35440004
[TBL] [Abstract] [Full Text] [Related]
19. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ; Rutkowski P; Queirolo P; Del Vecchio M; Mackiewicz J; Chiarion-Sileni V; de la Cruz Merino L; Khattak MA; Schadendorf D; Long GV; Ascierto PA; Mandala M; De Galitiis F; Haydon A; Dummer R; Grob JJ; Robert C; Carlino MS; Mohr P; Poklepovic A; Sondak VK; Scolyer RA; Kirkwood JM; Chen K; Diede SJ; Ahsan S; Ibrahim N; Eggermont AMM;
Lancet; 2022 Apr; 399(10336):1718-1729. PubMed ID: 35367007
[TBL] [Abstract] [Full Text] [Related]
20. Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.
Sala M; Allain N; Moreau M; Jabouille A; Henriet E; Abou-Hammoud A; Uguen A; Di-Tommaso S; Dourthe C; Raymond AA; Dupuy JW; Gerard E; Dugot-Senant N; Rousseau B; Merlio JP; Pham-Ledart A; Vergier B; Tartare-Deckert S; Moreau V; Saltel F
Oncogene; 2022 Apr; 41(18):2571-2586. PubMed ID: 35322197
[TBL] [Abstract] [Full Text] [Related]
[Next]
